摘要
目的探讨利格列汀联合二甲双胍治疗新诊断T2DM患者的临床疗效及安全性。方法采用随机数字表法将我院内分泌科2013年1~10月收治的140例新诊断T2DM患者分为利格列汀组（利格列汀＋二甲双胍）和格列吡嗪组（格列吡嗪＋二甲双胍）,各70例,疗程均为12周。比较两组降糖效果及安全性。结果治疗前两组FPG、2hPG及HbA_1c比较,差异无统计学意义（P〉0.05）;治疗后两组FPG、2hPG及HbA_1c较治疗前降低（P〈0.05）,治疗后两组间比较差异无统计学意义（P〉0.05）。治疗前两组FC-P、2hC-P、稳态模型评估胰岛β细胞功能指数（HOMA-β）、胰岛素抵抗指数（HOMA-IR）、胰岛素作用指数（IAI）及APN水平比较,差异均无统计学意义（P〉0.05）;治疗后两组较治疗前均好转（P〈0.05）,且利格列汀组优于格列吡嗪组（P〈0.05）。格列吡嗪组不良反应高于利格列汀组（18.57%vs 5.71%,χ^2=5.423,P=0.020）。结论利格列汀联合二甲双胍治疗新诊断T2DM与格列吡嗪联合二甲双胍降糖效果相同,且前者对胰岛β细胞功能保护作用更好,同时有利于提高APN水平。
Objective To explore the efficacy and safety of Linagliptin in combination with Metformin in newly diagnosed T2DM patients. Methods A total of 140 newly diagnosed T2DM patients were enrolled in this study.All the patients were admitted in the Endocrinology and Metabolism department of our hospital from January 2013 to October 2013.Random number table method was used in patients＇ selection.All the patients were divided into two groups：Linagliptin plus Metformin group（Linagliptin group,n=70）and Glipizide plus Metformin group（Glipizide group,n=70）,and followed up for 12 weeks.Efficacy and safety of treatment were compared between the two groups. Results The difference of FPG,2hPG and HbA_1c did not reach the statistical significance between the two groups at baseline treatment（P〉0.05）.FPG,2hPG and HbA_1c were significantly lower after treatment compared with baseline in both groups（P〈0.05）.FC-P,2hC-P,HOMA-β,HOMA-IR,IAI and adiponectin level at baseline were similar between the two groups（P〉0.05）.All these indicators were improved after treatment in both groups（P〈0.05）,and were significant better in Linagliptin group than in Glipizide group.Adverse events rate were significantly higher in Glipizide group than in Linagliptin group（18.57% vs 5.71%,χ^2=5.423,P =0.020）. Conclusion The efficacy of Linagliptin in combination with Metformin in newly diagnosed T2DM patients was similar with Glipizide plus Metformin.Theβcell function improvement was better and APN level was higher after Linagliptin treatment.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2015年第12期1073-1076,共4页
Chinese Journal of Diabetes
关键词
利格列汀
二甲双胍
糖尿病
2型
临床疗效
Linagliptin
Metformin
Diabetes mellitus
type 2
Clinical effect
